Vu H Duong1, Maria R Baer2, Franklin Hendrick3, Sheila R Weiss3, Masayo Sato3, Amer M Zeidan4, Steven D Gore4, Amy J Davidoff5. 1. University of Maryland Marlene and Stewart Greenebaum Cancer Center and Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA. Electronic address: vduong@umm.edu. 2. University of Maryland Marlene and Stewart Greenebaum Cancer Center and Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA. 3. Pharmaceutical Health Services Research Department, University of Maryland School of Pharmacy, Baltimore, MD, USA. 4. Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA. 5. Agency for Healthcare Research and Quality, Rockville, MD, USA.
Abstract
INTRODUCTION: Erythropoiesis-stimulating agents (ESAs) reduce red blood cell (RBC) transfusions in approximately 40% of patients with myelodysplastic syndrome (MDS) in clinical trials. We studied the association of timing of ESA initiation, agent (epoetin alfa, darbepoetin) and number of weeks of ESA use with response in MDS patients in routine practice. METHODS: Patients diagnosed with MDS from 2001 to 2005 were identified in the Surveillance Epidemiology and End Results-Medicare linked database. The study cohort consisted of patients with new-onset transfusion dependence (TD). All patients received an ESA at least once during the study period, which began the week that criteria for TD were met and continued until transfusion independence (TI). Kaplan-Meier statistics and Cox Proportional Hazard models were used to assess relationships between time to ESA initiation, agent and number of weeks of ESA use and TI attainment. RESULTS: Of 610 TD patients treated with ESAs, 210 (34.4%) achieved TI. Median time from ESA initiation to TI was 13 weeks. Shorter time from TD to ESA initiation and use of darbepoetin were associated with higher probability of achieving TI. The probability of achieving TI decreased beyond 8 weeks of treatment, and was very low beyond 16 weeks (8-15 weeks: HR=0.64, 16-31 weeks: HR=0.25, 32+ weeks HR=0.10). CONCLUSIONS: In this observational, population-based study, variations in ESA administration impacted response in transfusion-dependent MDS patients, with higher response rates with early administration and use of darbepoetin, and low response likelihood in non-responders beyond 16 weeks of therapy.
INTRODUCTION: Erythropoiesis-stimulating agents (ESAs) reduce red blood cell (RBC) transfusions in approximately 40% of patients with myelodysplastic syndrome (MDS) in clinical trials. We studied the association of timing of ESA initiation, agent (epoetinalfa, darbepoetin) and number of weeks of ESA use with response in MDSpatients in routine practice. METHODS:Patients diagnosed with MDS from 2001 to 2005 were identified in the Surveillance Epidemiology and End Results-Medicare linked database. The study cohort consisted of patients with new-onset transfusion dependence (TD). All patients received an ESA at least once during the study period, which began the week that criteria for TD were met and continued until transfusion independence (TI). Kaplan-Meier statistics and Cox Proportional Hazard models were used to assess relationships between time to ESA initiation, agent and number of weeks of ESA use and TI attainment. RESULTS: Of 610 TD patients treated with ESAs, 210 (34.4%) achieved TI. Median time from ESA initiation to TI was 13 weeks. Shorter time from TD to ESA initiation and use of darbepoetin were associated with higher probability of achieving TI. The probability of achieving TI decreased beyond 8 weeks of treatment, and was very low beyond 16 weeks (8-15 weeks: HR=0.64, 16-31 weeks: HR=0.25, 32+ weeks HR=0.10). CONCLUSIONS: In this observational, population-based study, variations in ESA administration impacted response in transfusion-dependent MDSpatients, with higher response rates with early administration and use of darbepoetin, and low response likelihood in non-responders beyond 16 weeks of therapy.
Authors: E Hellström-Lindberg; R Negrin; R Stein; S Krantz; G Lindberg; J Vardiman; A Ost; P Greenberg Journal: Br J Haematol Date: 1997-11 Impact factor: 6.998
Authors: Rami S Komrokji; Jeffrey E Lancet; Arlene S Swern; Nianhang Chen; Jennifer Paleveda; Richard Lush; Hussain I Saba; Alan F List Journal: Blood Date: 2012-08-30 Impact factor: 22.113
Authors: R Itzykson; S Thépot; O Beyne-Rauzy; S Ame; F Isnard; F Dreyfus; C Salanoubat; A L Taksin; Y Chelgoum; C Berthon; J V Malfuson; L Legros; N Vey; P Turlure; C Gardin; S Boehrer; L Ades; P Fenaux Journal: Leuk Res Date: 2011-12-15 Impact factor: 3.156
Authors: Amy J Davidoff; Sheila R Weiss; Maria R Baer; Xuehua Ke; Franklin Hendrick; Amer Zeidan; Steven D Gore Journal: Leuk Res Date: 2013-03-21 Impact factor: 3.156
Authors: Evangelos Terpos; Athina Mougiou; Alexandra Kouraklis; Aria Chatzivassili; Evridiki Michalis; Nicholas Giannakoulas; Eleni Manioudaki; Anna Lazaridou; Vassiliki Bakaloudi; Maria Protopappa; Dimitra Liapi; Elisavet Grouzi; Agapi Parharidou; Argyris Symeonidis; Garoufalia Kokkini; Nikolaos P Laoutaris; George Vaipoulos; Nikolaos I Anagnostopoulos; John I Christakis; John Meletis; Konstantinos L Bourantas; Nicholas C Zoumbos; Xenophon Yataganas; Nora-Athina Viniou Journal: Br J Haematol Date: 2002-07 Impact factor: 6.998
Authors: E Hellström-Lindberg; T Ahlgren; Y Beguin; M Carlsson; J Carneskog; I M Dahl; I Dybedal; G Grimfors; L Kanter-Lewensohn; O Linder; M Luthman; E Löfvenberg; H Nilsson-Ehle; J Samuelsson; J M Tangen; I Winqvist; G Oberg; A Osterborg; A Ost Journal: Blood Date: 1998-07-01 Impact factor: 22.113